|

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

RECRUITINGN/ASponsored by VisCardia Inc.
Actively Recruiting
PhaseN/A
SponsorVisCardia Inc.
Started2026-07-08
Est. completion2028-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites

Summary

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* NYHA classes II/III on optimal Guideline Directed Medical Therapy (GDMT) for 3 months
* EF≤ 40%
* At the time of consent, willing and able to comply with protocol requirements, including attending all required visits
* Willing to participate in the study and able to sign an informed consent form
* ≥18 years of age at the time of consent

Exclusion Criteria:

* Baseline 6-minute walk test \> 500 meters or \< 200 meters
* NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics
* Supine resting heart rate \> 140 bpm
* Systolic blood pressure \< 80 mmHg or \> 170 mmHg
* Serum creatinine \> 2.5 mg/dL
* Serum hepatic function 3x ULN
* Any of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/TIA, AF (episodes \> 24 hours), symptomatic NSVT or DCCV
* Any inotropic drug treatment within the previous 3 months
* Bradycardia (heart rate \< 50 beats/min), atrial arrhythmias with rates \> 100 beats/min, sustained ventricular tachycardia or frequent ventricular ectopy \>10% present during screening
* Significant uncontrolled symptomatic bradyarrhythmia, atrial fibrillation, unstable ventricular arrhythmias or frequent ventricular ectopy \> 10% documented within the previous 3 months
* Reversible non-ischemic cardiomyopathy
* Valvular disease requiring intervention within the next 12 months or presence of significant valve disease as determined by the site cardiologist as:

  1. Greater than mild mitral valve stenosis
  2. Greater than moderate mitral valve regurgitation
  3. Greater than mild tricuspid valve stenosis
  4. Greater than moderate-severe tricuspid valve regurgitation
  5. Greater than moderate aortic stenosis
  6. Greater than moderate aortic regurgitation
  7. Greater than mild-moderate pulmonic stenosis
  8. Greater than moderate pulmonic regurgitation
* Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys \>70 mmHg at rest
* Severe COPD, other respiratory or lung diseases where FEV1 \< 50%
* Presence of more than small pleural effusion or history of pleural drainage within the previous 6 months
* Known history of diaphragmatic paralysis or suspicion confirmed by unilateral or bilateral elevation of the diaphragm on chest x-ray
* Pericardial disease
* Non-cardiac condition substantially impairing ambulation of 6-minute hall walk test interpretation
* Existing diaphragmatic stimulation for respiration assist
* Present LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months)
* Contraindications to laparoscopic access to the diaphragm, as determined by the implanting physician
* Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm.
* Previous open laparotomy within 1 year
* Previous thoracic or abdominal organ transplant
* Drug induced immuno-suppression
* Body mass index \> 40
* Enrollment in a concurrent investigation / clinical study
* Having a life expectancy of \<1 year due to any condition
* Pregnant or planning a pregnancy during the study period
* Known allergies to implantable device materials
* History of systemic infection requiring the use of intravenous antibiotics within the previous 3 months
* Received cardiac resynchronization therapy (CRT) within six months of randomization, or is actively receiving CRT
* Currently have a Class I indication for a cardiac resynchronization therapy (CRT) device according to AHA/ACC/ESC guidelines for the treatment of congestive heart failure

Conditions2

Heart DiseaseHeart Failure With Reduced Ejection Fraction

Locations4 sites

Indiana

1 site
Ascension St. Vincent Hospital
Sangita Sudharshan(317) 338-6666sangita.sudharshan@ascension.org

Oklahoma

1 site
Saint Francis Hospital
Tulsa, Oklahoma, 74136
Ralph D Ensley, MD(918) 494-8500

Pennsylvania

1 site
University of Pennsylvania
Aditya Parikh, MD(215) 615-4949

Texas

1 site
Baylor College of Medicine
Houston, Texas, 77030
Ajith Nair, MD(713) 798-6230ajith.nair@bcm.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.